CA
NZ
UK
AU
IND
US
GeoVax, based in Atlanta, shifted its focus after the BARDA contract ended in April 2025 toward GEO-MVA, an MVA-based vaccine for mpox and smallpox, and Gedeptin, an oncolytic therapy for head and neck cancer. The European Medicines Agency advised that a Phase 3 immunobridging …
Savara is approaching the FDA's November 22, 2026 target action date for MOLBREEVI, its inhaled therapy for autoimmune pulmonary alveolar proteinosis, under Priority Review following a three-month extension granted earlier in 2026. The drug carries Fast Track, Breakthrough Therapy andOrphan Drugdesignations, and Savara (NASDAQ:SVRA) …
● MDT shares rose 1.84% to $87.97 on Monday, October 5, on 43.69 million shares, 2.31 times normal volume.
● MRNA shares rose 6.95% to $203.21 on Monday, October 5, on 19.31 million shares, about 1.16 times normal volume.
It's a crowded morning for biotech and healthcare names. Pivotal-trial headlines, a regulatory green light, a financing event, and an analyst call are all competing for attention before the bell, and the companies behind them are at very different stages of their stories.
On September 8, 2026 PDS Biotech announced a financing of up to USD 22.55 million led by Dr. Patrick Soon-Shiong, and on September 14 it announced an initial closing of about USD 11.3 million. At that closing it issued 16,502,870 shares, 23,498,156 pre-funded warrants …
On October 5, 2026 at 7:00 a.m. ET, Alector announced an exclusive global license giving Genentech worldwide rights to AL050, a brain-penetrant enzyme replacement therapy for Parkinson's disease built on the Alector Brain Carrier platform, designed to move drugs across the blood-brain barrier. Genentech …
HeartBeam said on October 5, 2026 that the FDA granted Breakthrough Device Designation to the HeartBeam System as a tool for assessing potential heart attacks at home. Its 3D ECG captures the heart's electrical signals from three non-coplanar dimensions, letting physicians review ECG information …
Aldeyra Therapeutics shares sank on Monday, Oct. 5, while the Nasdaq Composite set a record, and no company-specific catalyst was found to explain the decline.
Alector shares surged on Monday, Oct. 5, after the biotech licensed its early-stage Parkinson's and neurodegeneration program to Roche's Genentech for $100 million upfront and up to $1.17 billion in milestones.
Please wait processing your request...